Jyong Biotech Ltd. (MENS) Stock

NASDAQ: MENSHealthcare company in the biotechnology industry, based in New Taipei City, USA.

Jyong Biotech stock price chart

MENS interactive chart →

MENS stock quote & key statistics

Jyong Biotech earnings per share

Income →
Earnings per share

Jyong Biotech revenue & net income

Income →
RevenueNet income

Jyong Biotech annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$4.7M—
FY2024$0-$3.0M—
FY2023$0-$4.4M—
FY2022$0-$6.6M—
FY2021$0-$4.2M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Jyong Biotech Ltd.

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Jyong Biotech stock FAQ

What is the Jyong Biotech stock ticker symbol?

Jyong Biotech Ltd. trades on the NASDAQ under the ticker symbol MENS.

What sector and industry is Jyong Biotech in?

Jyong Biotech Ltd. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Jyong Biotech have?

Jyong Biotech Ltd. has about 27 full-time employees.

What were Jyong Biotech's revenue and earnings last fiscal year?

Jyong Biotech reported revenue of $0 and net income of -$4.7M in fiscal 2025.

When did Jyong Biotech go public?

Jyong Biotech stock began trading on June 17, 2025.

Biotechnology stocks

All Healthcare stocks →